Multiple oral dosing of ketoconazole increases dog exposure to ivermectin

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 3, 2007, Pages 311-318

  Hugnet, Christophe ^a   Lespine, Anne ^a   Alvinerie, Michel ^b  

^a CLINIQUE VÉTÉRINAIRE   (France)

^b CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLYCOPROTEIN P; IVERMECTIN; KETOCONAZOLE; KETOFUNGOL; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PROTEIN TRANSPORT; ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; DOG; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TOXICITY AND INTOXICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; INJECTIONS, SUBCUTANEOUS; IVERMECTIN; KETOCONAZOLE; MALE; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEIN; RANDOM ALLOCATION;

EID: 34848924630     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. McKellar, Q. A. and Benchaoui, H. A., Avermectins and milbemycins. J Vet Pharmacol Ther, 19(5): 331-51, 1996.
2. Dourmishev, A., Serafimova, D. and Dourmishev, L., Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol, 11(3): 247-51, 1998.
3. Molyneux, D. H., Bradley, M., Hoerauf, A., Kyelem, D. and Taylor, M. J., Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol, 19(11): 516-22, 2003.
4. Aquilina, C., Viraben, R. and Sire, S., Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. A case report and literature review. Dermatology, 205(4): 394-7, 2002.
5. Dourmishev, A. L., Dourmishev, L. A. and Schwartz, R. A., Ivermectin: pharmacology and application in dermatology. Int J Dermatol, 44(12): 981-8, 2005.
6. Lespine, A., Martin, S., Dupuy, J., Roulet, A., Pineau, T., Orlowski, S. and Alvinerie, M., Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship. Eur J Pharm Sci, 2006.
7. Pouliot, J. F., L'Heureux, F., Liu, Z., Prichard, R. K. and Georges, E., Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol, 53(1): 17-25, 1997.
8. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. and et al., Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77(4): 491-502, 1994.
9. Schinkel, A. H. and Jonker, J. W., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev, 55(1): 3-29, 2003.
10. Mealey, K. L., Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther, 27(5): 257-64, 2004.
11. Kwei, G. Y., Alvaro, R. F., Chen, Q., Jenkins, H. J., Hop, C. E., Keohane, C. A., Ly, V. T., Strauss, J. R., Wang, R. W., Wang, Z., Pippert, T. R. and Umbenhauer, D. R., Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdrla P-glycoprotein. Drug Metab Dispos, 27(5): 581-7, 1999.
12. Mealey, K. L., Northrup, N. C. and Bentjen, S. A., Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc, 223(10): 1453-5, 1434, 2003.
13. Mealey, K. L., Bentjen, S. A., Gay, J. M. and Cantor, G. H., Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11(8): 727-33, 2001.
14. Roulet, A., Puel, O., Gesta, S., Lepage, J. F., Drag, M., Soll, M., Alvinerie, M. and Pineau, T., MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol, 460(2-3): 85-91, 2003.
15. Roulet, A., Puel, O., Gesta, S., Drag, M., Soll, M., Alvinerie, M. and Pineau, T. (2001) in FEBS Advanced lecture course, Gossau, Austria ).
16. Edwards, G., Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J, 2 Suppl 1: S8, 2003.
17. Mackenzie, C. D., Geary, T. G. and Gerlach, J. A., Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J, 2 SuppI 1: S5, 2003.
18. Twum-Danso, N. A., Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J, 2 Suppl 1: S3, 2003.
19. Angarano, D. W. and Scott, D. W., Use of ketoconazole in treatment of dermatophytosis in a dog. J Am Vet Med Assoc, 190(11): 1433-4, 1987.
20. Legendre, A. M., Selcer, B. A., Edwards, D. F. and Stevens, R., Treatment of canine blastomycosis with amphotericin B and ketoconazole. J Am Vet Med Assoc, 184(10): 1249-54, 1984.
21. Sharp, N. J: and Sullivan, M., Use of ketoconazole in the treatment of canine nasal aspergillosis. J Am Vet Med Assoc, 194(6): 782-6, 1989.
22. Mason, G. D., Labato, M. A. and Bachrach, A., Jr., Ketoconazole therapy in a dog with systemic cryptococcosis. J Am Vet Med Assoc, 195(7): 954-6, 1989.
23. Feldman, E. C., Bruyette, D. S., Nelson, R. W. and Farver, T. B., Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism. J Am Vet Med Assoc, 197(1): 71-8, 1990.
24. Bourrie, M., Meunier, V., Berger, Y. and Fabre, G., Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther, 277(1): 321-32, 1996.
25. Maurice, M., Pichard, L., Daujat, M., Fabre, I., Joyeux, H., Domergue, J. and Maurel, P., Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Faseb J, 6(2): 752-8, 1992.
26. Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F. and Benet, L. Z., The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther, 58(1): 15-9, 1995.
27. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P. and Hebert, M. F., Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther, 62(1): 41-9, 1997.
28. Kuroha, M., Kuze, Y., Shimoda, M. and Kokue, E., In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. Am J Yet Res, 63(6): 900-5, 2002.
29. Kuroha, M., Azumano, A., Kuze, Y., Shimoda, M. and Kokue, E., Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos, 30(1): 63-8, 2002.
30. Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W. F., Shimoda, M. and Kokue, E., Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci, 91(3): 868-73, 2002.
31. Ward, K. W., Stelman, G. J., Morgan, J. A., Zeigler, K. S., Azzarano, L. M., Kehler, J. R., McSurdy-Freed, J. E., Proksch, J. W. and Smith, B. R., Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos, 32(2): 172-7, 2004.
32. Lifschitz, A., Virkel, G., Sallovitz, J., Sutra, J. F., Galtier, P., Alvinerie, M. and Lanusse, C., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet Parasitol, 87(4): 327-38, 2000.
33. Yamakoa, K., Tanigavara, K., Nokaguana K., Unot T., A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobio. Dyn., 4: 879-885, 1981.
34. Perrier, D. and Mayersohn, M., Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci, 71(3): 372-3, 1982.
35. Gokbulut, C., Karademir, U., Boyacioglu, M. and McKellar, Q. A., Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol, 135(3-4): 347-54, 2006.
36. Alvinerie, M., Tardieu, D., Sutra, J., DBojensen, G. and Galtier, P. (1994) in EAVPT International Congress, Edinburgh, Scotland.
37. Chiu, S. H., Taub, R., Sestokas, E., Lu, A. Y. and Jacob, T. A., Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab Rev, 18(2-3): 289-302, 1987.
38. Kuroha, M., Shirai, Y. and Shimoda, M., Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. J Vet Pharmacol Ther, 27(5): 355-9, 2004.
39. Ridtitid, W., Wongnawa, M., Mahatthanatrakul, W., Raungsri, N. and Sunbhanich, M., Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther, 30(3): 285-90, 2005.
40. Ogasawara, A., Kume, T. and Kazama, E., Effect of Oral Ketoconazole on Intestinal First-pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys. Drug Metab Dispos, (in press). 2006.
41. Grimm, S. W., Richtand, N. M., Winter, H. R., Stams, K. R. and Reele, S. B., Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol, 61(1): 58-69, 2006.
42. Kovarik, J. M., Beyer, D., Bizot, M. N., Jiang, Q., Shenouda, M. and Schmouder, R. L., Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol, 45(5): 514-8, 2005.
43. Ballent, M., Lifschitz, A., Virkel, G., Sallovitz, J. and Lanusse, C., Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab Dispos, 34(3): 457-63, 2006.
44. Laffont, C. M., Toutain, P. L., Alvinerie, M. and Bousquet-Melou, A., Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab Dispos, 30(6): 626-30, 2002.
45. Alvinerie, M., Dupuy, J., Eeckhoutte, C. and Sutra, J. F., Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing agent verapamil. Parasitol Res, 85(11): 920-2, 1999.
46. Molento, M. B., Lifschitz, A., Sallovitz, J., Lanusse, C. and Prichard, R., Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol Res, 92(2): 121-7, 2004.
47. Lifschitz, A. L., Virkel, G. L., Sallovitz, J. M., Pis, A., Imperiale, F. A. and Lanusse, C. E., Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J Pharm Pharmacol, 56(1): 61-7, 2004.
48. Kageyama, M., Namiki, H., Fukushima, H., Ito, Y., Shibata, N. and Takada, K., In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull, 28(2): 316-22, 2005.
49. Schwab, M., Eichelbaum, A and Fromm, M. F., Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol, 43: 285-307, 2003.
50. Eichelbaum, M., Fromm, M. F. and Schwab, M., Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit, 26(2): 180-5, 2004.